MK-677 vs CJC-1295
Side-by-side comparison of MK-677, CJC-1295 — mechanism, dosing, half-life, side effects, and research status.
| Attribute | MK-677 MK-677 (Ibutamoren) — Oral GH Secretagogue Growth Hormone | CJC-1295 CJC-1295 (Modified GRF 1-29) Growth Hormone |
|---|---|---|
| Basics | ||
| Molecular type | Non-Peptide GH Secretagogue | GHRH Analogue |
| Amino acids | — | 29 |
| Molecular weight | 624.8 Da | 3,368.9 Da |
| Half-life | ~24 hours | 30 min (without DAC) / 7–8 days (with DAC) |
| Route(s) | Oral | Subcutaneous, Intramuscular |
| Mechanism & Research | ||
| Primary mechanism | MK-677 mimics ghrelin's binding to GHSR-1a receptors, activating the same signalling cascade that endogenous ghrelin uses to stimulate GH release. As a small non-peptide molecule, it resists enzymatic degradation and is … | CJC-1295 binds GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and increasing GH pulse amplitude. Unlike native GHRH (half-life <10 minutes), the modified amino acid substitutions in CJC-1295 resi… |
| Research status | Research Compound | Research Compound |
| Evidence summary | MK-677 has one of the most extensive clinical datasets of any non-approved GH secretagogue, with Phase 1/2 trials across multiple populations including GH-deficient adults, elderly frail patients, and post-hip-fracture p… | Phase 1/2 trials with CJC-1295 with DAC confirmed dose-dependent IGF-1 elevation lasting up to 14 days after single injection. CJC-1295 without DAC's pulsatile profile is primarily studied in combination with GHRPs. |
| Protocol & Dosing | ||
| Typical dose | 10–25 mg/day | 100–200 mcg (without DAC); 2mg every 2 weeks (with DAC) |
| Frequency | Once daily | 2–3x daily (without DAC); biweekly (with DAC) |
| Duration | 8–16 weeks; some protocols run 6 months | 8–16 weeks |
| Timing | Bedtime (maximises nocturnal GH pulse; also reduces daytime appetite impact) | Without DAC: fasted, 2x daily ideally morning + bedtime. With DAC: any time, biweekly. |
| Safety | ||
| Common side effects |
|
|
| Contraindications |
|
|
| Anti-doping | Prohibited (WADA S2) | Prohibited (WADA S2) |
| Deeper reading | ||
| Related peptides | Ipamorelin, CJC-1295, GHRP-6 | Ipamorelin, Sermorelin, GHRP-2, Tesamorelin |
| Full profile | Read full MK-677 profile → | Read full CJC-1295 profile → |
Comparison data is compiled from each peptide’s individual profile. All values are drawn from peer-reviewed research and regulatory sources. For educational use only — not medical advice. Verify any protocol with a qualified healthcare provider.